RS57394B1 - Formulacije bispecifičnih aktivatora t-ćelija (bite) - Google Patents

Formulacije bispecifičnih aktivatora t-ćelija (bite)

Info

Publication number
RS57394B1
RS57394B1 RS20180777A RSP20180777A RS57394B1 RS 57394 B1 RS57394 B1 RS 57394B1 RS 20180777 A RS20180777 A RS 20180777A RS P20180777 A RSP20180777 A RS P20180777A RS 57394 B1 RS57394 B1 RS 57394B1
Authority
RS
Serbia
Prior art keywords
bites
bispecific
formulation
cell engagers
engagers
Prior art date
Application number
RS20180777A
Other languages
English (en)
Inventor
Carsten Olbrich
Thomas Bunte
Jonas Winter
Jörg Peters
Thomas Trill
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of RS57394B1 publication Critical patent/RS57394B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
RS20180777A 2012-11-06 2013-11-05 Formulacije bispecifičnih aktivatora t-ćelija (bite) RS57394B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12191493 2012-11-06
EP13786255.3A EP2916866B1 (de) 2012-11-06 2013-11-05 Formulierung für bispecific t-cell-engangers (bites)
PCT/EP2013/073024 WO2014072277A1 (de) 2012-11-06 2013-11-05 Formulierung für bispecific t-cell-engangers (bites)

Publications (1)

Publication Number Publication Date
RS57394B1 true RS57394B1 (sr) 2018-09-28

Family

ID=47143702

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180777A RS57394B1 (sr) 2012-11-06 2013-11-05 Formulacije bispecifičnih aktivatora t-ćelija (bite)

Country Status (27)

Country Link
US (1) US11052128B2 (sr)
EP (1) EP2916866B1 (sr)
JP (1) JP6321667B2 (sr)
KR (1) KR20150082328A (sr)
CN (1) CN104780940B (sr)
AR (1) AR093365A1 (sr)
AU (2) AU2013343638B2 (sr)
CA (1) CA2890166C (sr)
CY (1) CY1120391T1 (sr)
DK (1) DK2916866T3 (sr)
ES (1) ES2676468T3 (sr)
HK (1) HK1211215A1 (sr)
HR (1) HRP20181021T1 (sr)
HU (1) HUE038151T2 (sr)
IL (1) IL238615A0 (sr)
LT (1) LT2916866T (sr)
MX (1) MX367034B (sr)
NZ (1) NZ707895A (sr)
PL (1) PL2916866T3 (sr)
PT (1) PT2916866T (sr)
RS (1) RS57394B1 (sr)
RU (1) RU2679124C2 (sr)
SG (1) SG11201502730SA (sr)
SI (1) SI2916866T1 (sr)
TR (1) TR201809507T4 (sr)
TW (1) TWI615158B (sr)
WO (1) WO2014072277A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
AU2019351715A1 (en) * 2018-10-01 2021-04-22 Amgen Inc. Methods for reducing aggregation of bispecific antibodies
EP3897720A4 (en) * 2018-12-19 2022-12-07 City of Hope BAFF-R BISPECIFIC T-CELL ENGAGER ANTIBODY
CA3155125A1 (en) * 2019-10-25 2021-04-29 Chen Zhu Compositions and methods for minimizing protein loss at low protein concentrations
CN115968867B (zh) * 2023-03-21 2023-07-14 天津外泌体科技有限公司 外泌体冻干保护剂和外泌体冻干制剂的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1767225A1 (en) 2005-09-21 2007-03-28 Insense Limited Method for stabilisation of a protein solution by addition of hydroxyl radical quenchers and its sterilisation by ionising radiation
GB0626021D0 (en) 2006-12-29 2007-02-07 Insense Ltd The stabilisation of proteins
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN101687915B8 (zh) 2007-04-03 2018-08-03 安进研发(慕尼黑)股份有限公司 跨物种特异性CD3-ε结合结构域
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US7681537B2 (en) * 2008-08-17 2010-03-23 Cummins Intellectual Properties, Inc. Gas extractor for an engine coolant system
BRPI0919841A2 (pt) * 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
CA2764180A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP3235508B1 (en) * 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
SG10201602668VA (en) * 2011-04-22 2016-05-30 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof

Also Published As

Publication number Publication date
RU2679124C2 (ru) 2019-02-06
MX367034B (es) 2019-08-02
TW201438764A (zh) 2014-10-16
CA2890166C (en) 2023-08-15
LT2916866T (lt) 2018-07-25
PT2916866T (pt) 2018-07-10
CY1120391T1 (el) 2019-07-10
JP2015536938A (ja) 2015-12-24
HRP20181021T1 (hr) 2018-08-24
PL2916866T3 (pl) 2018-10-31
AR093365A1 (es) 2015-06-03
AU2013343638A1 (en) 2015-05-28
SI2916866T1 (en) 2018-08-31
CN104780940B (zh) 2017-11-07
NZ707895A (en) 2019-07-26
CN104780940A (zh) 2015-07-15
CA2890166A1 (en) 2014-05-15
TWI615158B (zh) 2018-02-21
MX2015005700A (es) 2015-08-20
US20150335706A1 (en) 2015-11-26
AU2013343638B2 (en) 2018-08-30
WO2014072277A1 (de) 2014-05-15
HK1211215A1 (en) 2016-05-20
TR201809507T4 (tr) 2018-07-23
US11052128B2 (en) 2021-07-06
SG11201502730SA (en) 2015-05-28
EP2916866B1 (de) 2018-04-04
DK2916866T3 (en) 2018-07-23
AU2018214096A1 (en) 2018-08-30
KR20150082328A (ko) 2015-07-15
ES2676468T3 (es) 2018-07-19
JP6321667B2 (ja) 2018-05-09
EP2916866A1 (de) 2015-09-16
RU2015121574A (ru) 2016-12-27
HUE038151T2 (hu) 2018-10-29
IL238615A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
IL236792A0 (en) Engineering of t-cell receptors
EP2839690A4 (en) SECURE ENVIRONMENT FOR A PARTICIPANT
EP2846538A4 (en) IMAGE FORMING DEVICE
EP2858342A4 (en) IMAGING DEVICE
EP2881775A4 (en) IMAGING DEVICE
EP2787722A4 (en) IMAGE FORMING DEVICE
EP2878999A4 (en) VEHICLE BOARD CAMERA
EP2901206A4 (en) PORTABLE DEVICE
EP2858210A4 (en) DEVICE FOR ACTIVATING MULTI-BMS
EP2833095A4 (en) IMAGING DEVICE
EP2904973A4 (en) RADIOGRAPHY DEVICE
EP2926649A4 (en) FOCUSING DEVICE
EP2868430A4 (en) JIG
HK1215709A1 (zh) 奧普佐米 的調節釋放製劑
EP2750373A4 (en) IMAGEUR DEVICE
HK1211215A1 (en) Formulation for bispecific t-cell engagers (bites) t(bites)
HK1210075A1 (en) Device for increasing microcirculation
GB2549901B (en) Devices for Blending Materials
EP2833614A4 (en) IMAGING DEVICE FOR WELDING
EP2842686A4 (en) JIG
GB2506398B (en) Camera apparatus
HK1245418B (zh) 曝光裝置
EP2875851A4 (en) CRYSTALLIZATION DEVICE
PL2712817T3 (pl) Urządzenie do opinania
EP2897458A4 (en) DEVICE FOR FISHING